January 18, 2024
Takeda Pharmaceutical said on January 16 that its immunoglobulin Hyqvia is now approved in the US as a maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP). Hyqvia was first granted approval in the US in 2014 for primary immunodeficiency (PI)...read more